Small-cap biopharmaceutical Amarin (NASDAQ: AMRN )
has made it clear that the company is not giving up on Vascepa without
a fight, several of them actually. In addition to challenging the FDA's
decisions to rescind a Special Protocol Assessment (SPA) on the
company's ANCHOR study and to refuse NCE status for the key ingredient
in Vascepa, the company is now trying to augment its sales effort. A
co-promotion agreement with Kowa Pharmaceuticals America will most
likely cap the company's gross margin for the foreseeable future, but it
adds nearly twice as many reps as Amarin has pushing the drug.
Please read the full article here:
Can This Drive Growth for Amarin Corporation plc?
No comments:
Post a Comment